A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial

Eur J Cancer. 1992;29A(1):33-6. doi: 10.1016/0959-8049(93)90572-w.

Abstract

151 patients (149 evaluable) receiving their first course of chemotherapy containing cisplatin in a dose of at least 50 mg/m2 were randomised to receive either a single dose of intravenous granisetron 80 micrograms/kg or intravenous metoclopramide 2 mg/kg every 2 h for five doses plus a single dose of dexamethasone 10 mg and diphenhydramine. After 24 h, there was no significant difference between groups with respect to nausea or vomiting: in the granisetron group 46% of patients had no emesis, versus 44% of the standard group. Granisetron is an antiemetic agent with efficacy similar to that of high-dose metoclopramide plus dexamethasone.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Antiemetics / therapeutic use*
  • Cisplatin / adverse effects*
  • Dexamethasone / therapeutic use
  • Diphenhydramine / therapeutic use
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Granisetron
  • Humans
  • Indazoles / therapeutic use*
  • Male
  • Metoclopramide / therapeutic use
  • Middle Aged
  • Nausea / chemically induced
  • Nausea / prevention & control
  • Vomiting / chemically induced
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Indazoles
  • Dexamethasone
  • Diphenhydramine
  • Metoclopramide
  • Cisplatin
  • Granisetron